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Abstract 
Life threatening infection as an adverse reaction to cytotoxic therapy of cancer remains a 
major problem, potentially limiting efficacy. Administration of colony-stimulation factors 
benefits only a minority of patients and improved stratification guidelines are needed to 
identify those patients likely to benefit.  
 
We investigated single nucleotide polymorphisms (SNPs) in two genes related to immune 
function to identify associations with severe infection following treatment of breast cancer 
with doxorubicin and cyclophosphamide. CD95 mediates the extrinsic apoptosis pathway in 
haematopoietic cells and a CD95 promoter SNP (rs2234767) has been shown to result in 
reduced expression of the receptor. MBL2 activates the classical complement pathway in 
the presence of pathogens and independently of antibodies. Numerous SNPs have been 
described including a promoter SNP (rs7096206) which results in decreased expression of 
the protein. 
 
 Homozygotes for the CD95 minor allele were more likely to experience a grade 3 infection 
than heterozygote and homozygote wild-type patients (29%, 3% and 5% respectively p = 
0.048). CD95 minor allele homozygotes also had higher basal WBC and neutrophil counts 
compared with wild-type allele carriers, which was sustained throughout therapy. There 
was an allele-dose association between the MBL2 SNP and grade 3 infection, with 2, 8 and 
17% of wild-type homozygotes, heterozygotes and minor allele homozygotes, respectively, 
experiencing grade 3 infection (p = 0.02).  
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These associations demonstrate the utility of a pharmacogenetic approach to identify 
individuals more likely to acquire a life threatening infection during chemotherapy. The 
apparent association with a CD95 SNP and a mild neutrophilia merits further investigation. 
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Introduction 
Despite recent advances in the development of targeted therapies for the treatment of 
cancer, most patients will still receive cytotoxic drugs as part of the management of their 
disease. Cytotoxic therapy is associated with serious infection, coupled with febrile 
neutropenia, and is a cause of morbidity and mortality. A significant minority (15%) of 
breast cancer patients experience at least one episode of febrile neutropenia during 
cytotoxic chemotherapy, in the absence of prophylactic colony stimulating factor [1].  While 
mortality due to infection remains low, serious therapy-induced infection may result in a 
dose delay or dose reduction, which may result in decreased antitumour effect and a worse 
survival outcome [2]. Colony stimulating factors (G-CSF or GM-CSF) during cytotoxic 
chemotherapy are commonly used to reduce the incidence of febrile neutropenia among 
those deemed at highest risk according to current guidelines [3]. However, a recent 
Cochrane review of trials testing efficacy and toxicity reported that less than 10% of patients 
benefit from prophylactic CSF, and that adverse reactions, including bone pain (43%) and 
injection inflammation (55%), are common [1]. Therefore there is a need to identify those 
patients at greatest risk of chemotherapy-related grade 3 infections, and most likely to 
benefit from CSF therapy or to be in need of more intense monitoring during chemotherapy.  
Identification of variation in genes associated with immunological mechanisms offers one 
possible way of identifying patients with increased susceptibility to chemotherapy-induced 
infection. We therefore investigated two genes encoding proteins known to have a function 
in the immune response, CD95 and MBL2, both of which have functional polymorphic 
variants. 
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CD95 (FAS, APO-1, APT1), when activated by FAS ligand (CD95L), mediates cell death via the 
extrinsic apoptosis pathway and regulates hematopoietic homeostasis [4].  A well-studied 
SNP within the CD95 gene promoter (rs2234767 -1377G>A), which disrupts an SP-1 binding 
site and is associated with lower expression of CD95 [5] and has been associated with 
increased risk of acute myeloid leukemia [5] and poorer prognosis in acute promyelocytic 
leukemia [6] . There are also indications that a functional CD95 pathway participates in 
doxorubicin-induced apoptosis in leukemia cell lines [7]. 
MBL2 is a secreted hepatic protein component of the innate immune system. The primary 
structure contains a carbohydrate recognition domain and a collagen-like domain 
comprising of 19 Gly-Xaa-Yaa repeats [8]. The triple helix formation of the collagen motif 
results in the formation of a homotrimer. These structures in turn form a higher order 
polymeric structure with multiple mannan-binding domains per single quaternary structure 
[9]. This higher order structure can recognise pathogens and initiate the classical 
complement pathway independently of antibodies [10] and facilitate phagocytosis [11]. Five 
common polymorphisms of the MBL2 gene have been extensively studied [9] (Figure S1a). 
Three of these are located on exon 1, encoding the collagen-like motif.  Two are non-
synonymous SNPs, termed MBL2 B (rs1800450) and C (rs1800451), that result in 
substitution of glycine residues and disrupt the formation of the tertiary structure [12, 13]. 
The third exon 1 SNP (MBL2 D, rs5030737) codes for a cysteine to arginine substitution in 
the collagen-like domain. This does not disrupt the canonical  motif sequence, but may 
contribute to loss of higher order structure [14], although the effect of the D allele on the 
concentration of functional MBL in plasma is less than that seen with the other two coding 
SNPs [15, 16]. There have been suggestions that the exon 1 SNPs, in addition to the loss of 
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the collagen-like structure, may also result in decreased protein expression compared to 
wild type. However a greater effect on expression of the MBL2 monomer of the protein may 
result from two promoter polymorphisms [17]. We chose for this study to investigate 
polymorphisms that had the greatest magnitude effect on expression of the monomer. 
We therefore studied the impact of functional SNPs in the MBL2 and CD95 genes on risk of 
chemotherapy-induced infection in breast cancer patients treated with doxorubicin 
(Adriamycin) and cyclophosphamide (AC) therapy and subject to uniform follow up. 
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Methods 
Patient populations 
A total of 364 women with breast cancer were recruited to this study from medical oncology 
outpatient clinics in the Newcastle upon Tyne NHS foundation trust. A whole blood sample 
for extraction of genomic DNA was collected from all 364 patients and a plasma sample was 
taken from 101 (30%) patients.  
Two hundred and sixty five of the patients were treated with a chemotherapy regimen of 60 
mg/m2 doxorubicin and 600 mg/m2 cyclophosphamide, administered intravenously on day 1 
of each 21 day cycle for a maximum of six cycles. Clinical data were collected from patient 
notes and from the Trust laboratory and Patient Administration Service (PAS) databases. 
Median follow-up time was 74 months (range 2 to 120 months) and this follow up was 
uniform with patients attending clinic every three months from the time of treatment for 
the first two years, every six months from two to five years and thereafter annually for up to 
ten years. Grade 3 infections in this study are defined as those where the patient required 
hospital admission and treatment during therapy. The “any infection” category includes all 
self-reported incidences not requiring treatment.  These 265 samples are homogenous for 
AC therapy and follow-up and represent the main cohort for the assessment of associations 
between genotype, infection and haematopoietic parameters. Pharmacogenetic studies 
based on 227 of the patients who received AC adjuvant therapy have previously been 
published[18-20]. 
All patients gave written informed consent and the study was given ethical approval by the 
Newcastle and North Tyneside Research Ethics Committee I. 
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MBL2 ELISA 
Circulating MBL2 concentration in plasma was measured using a commercial ELISA kit 
(Human MBL ELISA kit, R&D, Abingdon UK) as per the manufacturer’s instructions. Briefly, 
96-well plates were incubated overnight at room temperature (RT) with 0.8 µg/ml capture 
antibody in PBS. Plates were then washed three times with 0.2 µm filtered wash buffer of 
0.05% Tween20 (Sigma, Poole, UK) in PBS (Life, Paisley, UK) and incubated for 1 hour at RT  
in a 0.2 µm filtered solution of 1% BSA (Sigma, Poole, UK) in PBS. Patient plasma samples 
were diluted 1:750, 1:1750 or 1:4000 in 1% BSA solution and added to the plate in triplicate 
and incubated for two hours at RT. After further washing, the plates were incubated with a 
Biotinylated anti-MBL antibody (R&D Systems) for two hours at RT, washed and incubated 
for 20 minutes at room temperature with a Streptavidin conjugated HRP solution (R&D 
Systems). After a final wash the plates were incubated for 20 minutes at room temperature 
in a 1:1 solution of H2O2 and tetramethylbenzidine (Thermo Scientific, Loughborough, UK). 
The reaction was stopped with the addition of 2N Sulphuric acid and the absorbance read at 
450 and 540 nm on a Fluostar omega spectrophotometer (BMG, Offenburg, Germany).  The 
A450-A540 value was used to determine the concentration by interpolation of a seven point 
standard curve and corrected for dilution. 
 
DNA and Plasma extraction 
 A 10 ml volume of whole blood was taken from each patient into an EDTA tube and stored 
at -20oC prior to extraction of DNA. DNA was extracted using a QIAmp Maxi Blood kit 
(Qiagen, UK) as per manufacturer’s instructions. The quantity and quality of DNA was 
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determined by measuring absorbance between 220 and 750 nm using a Nanodrop ND-1000 
(Thermo scientific, Loughborough, UK). Samples from which plasma was isolated were 
centrifuged at 2000 g for 10 minutes and the plasma removed. Cellular and plasma fractions 
were stored at -20oC priors to DNA extraction and analysis. 
 
Genotyping 
Genotyping was performed using Taqman Assays on demand as per the manufacturer’s 
instructions (Applied Biosystems). The primer/probe kits were:- rs7096206, 
C_27858274_10; rs5030737, C_2336610_10; rs1800450, C_2336609_20;  rs1800451, 
C233608-20, all in the MBL2 gene and   rs2234767, C_12123966_10 for the CD95 SNP. 
For MBL2 rs1103125 the following primers and probes were designed using the Taqman 
custom assays algorithms; Primer 1 GATCAACCTCAACCTTAGTCACCAA, Primer 2 
CACTCTGCCAGGGCCAA Probe 1 CAAGCCTGTCTAAAACA, Probe 2 CAAGCCTGTGTAAAACA. 
The custom assay PCR was run under standard Taqman conditions. 
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Results 
MBL2 Genotype-phenotype relationship 
Before investigating the impact of MBL2 SNPs on clinical parameters we wanted to 
determine whether individual SNP or haplotype status was associated with plasma MBL2 
protein levels measured by ELISA. The distribution frequency of each of the MBL2 SNPS was 
determined in 363 of the patients from whom germline DNA was extracted (Table 1). All 
SNPs 3’ of the promoter G-550C SNP were in linkage disequilibrium (LD) and two of the 
exonic SNPs were in LD with the G-221C promoter SNP. The exonic SNPs were not in LD with 
each other (Figure S1b).  
The impact of each of the SNPs on the plasma concentration of MBL2 was measured in 101 
breast cancer patients for whom both genomic DNA and plasma samples were available. All 
the SNPs, other than the exonic G170A SNP (rs1800451, MBL2 C), demonstrated an allele 
dose response, with lower concentrations of MBL2 being associated with alleles predicted 
from the literature to be associated with low expression or function (figure S1c). The largest 
magnitude effect was seen with the -221 SNP with 7/7 patients homozygous for this SNP 
having less than 100 ng/ml plasma MBL2, compared with 2/63 homozygous WT and 6/31 
heterozygous patients (p < 0.0001, Fisher’s exact test). The seven homozygous patients for 
the -221 variant had a mean MBL2 concentration of 32 ± 15 ng/ml and were WT 
homozygotes for all other MBL2 SNPs investigated. Combining SNPs into haplotypes as 
previously described did not increase the magnitude of the effect [21]. Therefore, the 
rs7096206 SNP was used to investigate the impact of MBL2 genotype on infection and 
survival. 
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SNP genotype status and association with clinical and demographic features.  
Genomic DNA samples from 265 breast cancer patients, with comprehensive and 
standardised follow-up data after receiving AC chemotherapy, were genotyped for the CD95 
G-1377A and MBL2 G-221C promoter SNPs (264 genotypes for each SNP, due to failed 
genotyping in 1 case each). There was no evidence of deviation from Hardy-Weinberg 
equilibrium (HWE) for either SNP (p = 0.405 and 0.598 respectively, 2 test), and the 
frequency distributions were broadly in agreement with 1000 genomes phase 3 European 
cohort data [22]. The mean age of the cohort at recruitment was 58 years and there was no 
association between age and genotype for any of the variants investigated (data not 
shown). There was no association between MBL2 genotype and tumour hormone receptor 
status, stage, grade, focality, nodal involvement or metastatic disease. (Table 2). Likewise, 
there was no association between CD95 genotype for any of the clinical parameters 
investigated, with the exception of focality (p=0.045, Table 2), although this was not 
reflected in a clear gene dose response. 
 
CD95 and MBL2 genotype in relation to risk of Infection or survival 
There was a significant association between CD95 SNP status and infection subsequent to 
chemotherapy (Figures 1a & b). Specifically, 2 of 7 (29%) homozygotes for the minor allele 
experienced a grade 3 infection, compared to 2/65 (3%) heterozygotes and 10/192 (5%) 
homozygotes for the common allele (p=0.048, Fisher’s exact test). Likewise, 5 of 7 (71%) 
homozygotes for the minor allele experienced an infection (of any grade), compared to 
21/65 (32%) heterozygotes and 60/192 (31%) homozygotes for the major allele (p=0.047, 
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Fisher’s exact test). Although not significant when corrected for multiple testing, these data 
suggest a recessive genetic model, whereby homozygosity for the minor allele is associated 
with increased risk of infection post-chemotherapy. 
There was a significant association between the MBL2 -221 allele dose and grade 3 infection 
during chemotherapy with frequencies of 3, 8 and 17% (p= 0.02, Fisher’s exact test) for wild 
type homozygotes, heterozygotes and minor allele homozygotes, respectively (Figure 1c), 
suggesting an additive genetic model between this variant and incidence of high-grade 
infection. However, there was no apparent association between MBL2 genotype and risk of 
infection considering all grades (p = 0.404, Fisher’s exact test, Figure 1d)). 
In addition to the increased risk of infection associated with homozygosity for the CD95 
minor allele, the same individuals had significantly higher white blood cell (WBC) count (p 
<0.0001, 2-way ANOVA), neutrophil count (p <0.0001, 2-way ANOVA) and hemoglobin (p = 
0.0002, 2-way ANOVA) prior to chemotherapy and following each subsequent cycle of 
chemotherapy (Figure 2). A statistically significant higher WBC count in MBL2 -221 minor 
allele homozygotes (p = 0.01, 2-way ANOVA) was not sustained over the course of therapy 
and was not accompanied by a difference in neutrophil count. (Supplementary figure 2). 
Despite clear evidence for an association with high grade infection, there was no significant 
association between either the MBL2 -221 or CD95 genotype and progression-free or overall 
survival (Figure 3).  
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Discussion 
MBL2 genotype and risk of infection 
MBL2 has a well characterised role in the innate immune response, facilitating the classical 
complement pathway independently of antibodies [10, 23].  The importance of this pathway 
has been illustrated by the immune deficiency reported in individuals unable to opsonise 
saccharomyces cerevisiae [12, 24], a condition which may be treatable by MBL2 
replacement therapy [25]. It seems likely that this pathway is even more essential during 
periods of compromised cellular immunity, where in the absence of neutrophils, MBL2-
mediated complement activation can cause lysis of pathogens. Numerous studies in 
pediatric and leukemic populations receiving cytotoxic therapy have examined the potential 
association between low circulating higher order polymeric structure MBL2 or MBL2 
genotype and frequency of infection. While some studies have revealed an association with 
MBL2 phenotype and infection [26, 27] others have not [28, 29] and this inconsistency may 
be due to population heterogeneity and use of different markers of MBL2 function. There 
has been only one study into the association of MBL2 genotype with infection following 
cytotoxic therapy in solid tumours, in which febrile neutropenia in irinotecan-treated 
patients was associated with the -550 G variant. [21] 
MBL2 genetics are frequently reported as seven common haplotypes, encompassing the 
three structural and two promoter polymorphisms. In practice, the presence of any one of 
the three exonic SNPs (B,C and D) is frequently reported as O and any phenotypic effect of 
promoter SNPs is considered only in individuals who are homozygous WT for the exonic 
SNPs [9]. While these haplotypes are associated with high, intermediate and low circulating 
levels of MBL2 of a higher order structure, they may not have any effect on the plasma 
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concentration of the monomer. For example the D allele has minimal effect on higher order 
structure in heterozygotes and no effect on expression of the primary structure, compared 
with the B allele which has a large effect on quaternary structure and is associated with 
lower circulating levels of the monomer [16, 17, 30]. We therefore chose to take an 
unbiased approach to the MBL2 genotyping, aiming to establish which SNP in our 
population was associated with lower circulating levels of the MBL2 monomer. The -221 
promoter polymorphism had the largest effect on circulating MBL2 monomers, based on a 
polyclonal ELISA assay, in the patients in our population from whom we had plasma 
samples. In contrast, the compound exonic haplotype (A/O and O/O vs AA) had less effect 
on circulating MBL2 monomer than the -221 promoter SNP alone and the effect was not 
enhanced by inclusion of the -221 or -550 SNPs in A/A individuals. 
We therefore chose to use the -221 SNP alone to test for association with infection in the 
patients in our cohort who received uniform therapy and follow-up. The clear gene-dose 
effect between this polymorphism and grade 3 infection indicates that measurement of the 
MBL2 monomer rather than direct measurement of the higher order structures per se may 
have a role in predicting likelihood of serious infection in response to cytotoxic therapy. 
 
 
The CD95 rs2234767 SNP 
We report here an association between CD95 genotype (rs2234767) and risk of infection in 
breast cancer patients post-chemotherapy. Our data also identify an association between 
CD95 genotype and WBC, neutrophil count and haemoglobin levels in cancer patients. 
Following activation by ligand binding, the CD95 receptor initiates the assembly of a 
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signalling complex that promotes cell death [31]. The CD95 signalling pathway plays a key 
role in cellular homeostasis, including elimination of self-reactive B-lymphocytes [32], 
megakaryocyte cell death [33], and regulating T-lymphocyte homeostasis [34].  CD95 also 
mediates neutrophil cell death [35]. Redundancy in pro-apoptotic stimuli of neutrophil 
apoptosis is likely and apoptosis independent of CD95L:CD95 interaction does occur [35].  
However, CD95L induced apoptosis is not seen in CD95 deficient mice [36] and a CD95 
blocking antibody has been shown to abrogate CD95L induced apoptosis of human 
neutrophils ex-vivo  [37]. As such, putatively low expression of the receptor conferred by 
homozygosity for the rs2234767 minor allele may result in a failure to eliminate neutrophils 
and concomitantly higher baseline numbers of this cell type, as seen in the breast cancer 
patients in our study.  Congenital disorders in neutrophil proliferation and function are 
associated with infant morbidity and mortality, and are typically characterised by 
neutropenia and immunodeficiency  [38]. In contrast, CD95 deficient mice have an 
autoimmune phenotype [39] and mutations in CD95 or CD95L cause a rare human 
pathology, autoimmune lymphoproliferative disorder (ALPS), although a proportion of ALPS 
patients are neutropenic[40]. Given the allelic frequency of the rs2234767 SNP, 
homozygosity is unlikely to be associated with the severe congenital syndromes seen with 
other neutrophil dysfunction phenotypes. The novel observation that the CD95 rs2234767 
SNP is associated with a basal and sustained mild neutrophilia in this cohort is consistent 
with the functional impact of the SNP and the function of the protein and needs 
confirmation and characterisation in further cohorts. Although the clinical significance of 
this observation requires further validation, it is tempting to speculate that the higher WBC 
count in patients with the variant allele is also associated with impaired activity of these 
neutrophils, leading to a greater risk of infection. 
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CD95 also plays a role in mediating apoptosis induced by the cytotoxic chemotherapeutic 
agents, including cyclophosphamide and doxorubicin, used to treat many cancers[41]. 
Compromised efficacy of chemotherapy as a result of CD95 dysfunction (or low receptor 
expression) can confer poor prognosis[42, 43] and susceptibility to infections concomitant 
with progressive late-stage cancer. Sunter and colleagues (2012) reported significantly lower 
overall and progression-free survival in APL patients carrying at least one copy of the minor 
rs2234767 allele, and risk of infection-related death was significantly higher in this patient 
group[6]. Functional analysis demonstrated that the SNP affects an SP1 transcription factor 
binding site and that the variant allele is associated with low transcription factor binding and 
lower CD95 transcription, which is predicted to render cells resistant to chemotherapy-
induced apoptosis. The absence of an impact on survival of the rs2234767 minor allele in 
the breast cancer cohort reported here is in contrast to the APL findings, although the 
current study is relatively underpowered. Nevertheless, it remains possible that the minor 
rs2234767 allele may also have a direct impact on immune function and subsequent risk of 
infection, independent of any effect on infection risk due to underlying progressive cancer.  
It should also be acknowledged that the results of this retrospective study require validation 
in an independent dataset. 
 
Conclusion 
We have identified two SNPs in two immune related genes that have an association with 
severe and potentially life-threatening infection following doxorubicin and 
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cyclophosphamide therapy for breast cancer. It should be acknowledged that susceptibility 
to infection is multi factorial, and that any relationship between a gene and a single 
phenotype could be affected by confounding variables. Nevertheless, these data suggest 
CD95 and MLB2 genotype could aid in the identification of patients at high risk of serious 
infection, and who may benefit from prophylactic CSF therapy. 
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Table 1) 
 
 
 
                                          
 Table 1) MBL2 genotype frequency in breast cancer patients  
  
     SNP  
 rs# rs11003125 
 rs7096206  rs5030737  rs1800450  rs1800451  
 Nucleotide C-550G 
 G-221C  C154T  G161A  G170A  
 Protein  
    R52C  G54D  G57E  
 Nomenclature L/H 
 Y/X  A/D  A/B  A/C  
 
Function Increased Expression 
 
Decreased 
Expression 
 Decreased 
oligormerisation 
 
Decreased 
oligormerisation 
 Decreased 
oligormerisation 
 
                      
 
  No. (%) 
 
 No. (%)   No. (%) 
 
 No. (%)   No. (%) 
 
 
Genotype 
CC 150 (41.3) GG 215 (59.2) CC 321 (88.4) GG 277 (76.3) GG 342 (94.2) 
 CG 167 (46.0) GC 123 (33.9) CT 42 (11.6) GA 81 (22.3) GA 21 (5.8)  
 GG 46 (12.7) CC 25 (6.9)      AA 5 (1.4)      
 total 363    363    363    363    363   
                      
 MAF (%)  35.7    23.8    5.8    12.5    2.9   
                      
 HWE (p 
for2) 
  0.964       0.205       0.242       0.736       0.570    
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Table 2 
 
 
 
 
Table 2) Frequency distribution of MBL2 promoter and CD95 SNPs in clinical parameters. 
    MBL2 -221 (rs7096206) 2 (p)  CD95 (rs2234767) 2 (p) 
    Total   
wt 
(GG) 
het 
(GC) 
var 
(CC) 
    
wt 
(GG) 
het 
(GA) 
var 
(AA)  
  
All  264*  154 92 18 0.405c  192 65 7 0.598c 
             
ER Negative   
262 
 37 25 6 
0.551a 
 51 15 1 
0.909a 
ER Positive    116 67 11  141 49 5 
             
PR Negative   
250 
 52 35 8 
0.306b  
 74 19 1 
0.392a 
PR Positive    97 51 7  110 41 4 
             
Size             
< 20.0mm   
261 
 62 37 9 
0.661a 
 80 25 3 
0.956a 
20.0-
49.9mm  
  74 48 8  93 33 4 
50.0mm+   16 6 1  16 7 0 
             
Grade             
Grade I   
260 
 14 6 0 
0.271a 
 16 4 0 
0.977a Grade II    71 35 7  82 29 3 
Grade III    65 51 11  90 32 4 
             
Focality             
Unifocal   
262 
 132 75 16 
0.723a 
 167 48 7 
0.045a 
Multifocal    21 16 2  24 16 0 
             
Nodes             
0  
260 
 86 58 12 
0.222b 
 112 39 4 
0.931a 
1 or more   66 32 6  78 24 3 
             
 
Metastases 
            
Detected  
264 
 3 3 1 
0.354a 
 4 2 1 
0.174a Not 
Detected 
  151 89 17  188 63 6 
                          
 aFishers exact test. bPearson Chi-square. cHWE Chi-square. *263 patients were common to both 
genotypings, the 264 sample in both cohorts is not the same person. 
25 
 
Figure legends 
Figure 1 
Frequency (percentage) of Grade 3 infection (a & c) and any (b & d) infection following the 
first three cycles of doxorubicin and cyclophosphamide chemotherapy for breast cancer. 
Patients are categorised according to genotype for  CD95 rs2234767 (a&b) or MBL2-221 
rs7096206 (c&d) genotypes (wt = wild-type, Het = heterozygote, v = variant). 
Figure 2 
Blood counts (White Blood Cells, Neutrophils, Haemoglobin and Platelets) in breast cancer 
patients during doxorubicin and cyclophosphamide chemotherapy according to CD95 
genotype (wt = wild-type, Het = heterozygote, v = variant).  
Figure 3  
Kaplan-Meier curves for Overall Survival (a & c) and Progression Free Survival (b & d) of 
breast cancer patients treated with doxorubicin and cyclophosphamide chemotherapy 
according to MBL2-221 rs7096206 genotype (a & b) or CD95 rs2234767 genotype (c & d). 
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Figure 2 
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Figure 3 
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Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 
infection following adjuvant therapy for breast cancer with doxorubicin and 
cyclophosphamide. 
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Figure S1 
a) MBL2 gene structure illustrating positions of SNPs. 
b) Linkage disequilibrium of MBL2 SNPs in a cohort of 363 breast cancer patients showing D’ 
values on the bottom left side of the matrix and Fisher’s exact 2 sided p values on the top 
right half.  
c) Impact of MBL2 SNPS on expression of mean MBL in plasma of 101 of the patients. The 
solid lines illustrate the mean values associated with individual SNPS and the dashed lines 
with haplotypes constructed from precedents in the literature. Predicted MBL level 
phenotypes are assigned to individual genotypes and haplotypes according to the literature 
as follows: 
For the promoter SNP rs11003125 the minor allele is associated with greater expression. 
For the promoter SNP rs7096206 the minor allele is associated with lower expression. 
For all three of the exon 1 SNPs the minor allele is associated with lower activity. 
For the promoter haplotype individuals with at least one minor allele for the rs11003125 
SNP and wild type for the rs7096206 SNP were assigned to the high phenotype group. 
Individuals with at least one minor allele for the rs7096206 SNP and wild type for 
rs11003125 the SNP were assigned to the low phenotype group. All others were assigned to 
the intermediate group. 
For the exon haplotype any minor allele for the exon 1 SNPS was assigned the allelic 
designation O and a major allele for all three SNPs assigned the designation A. Individuals 
31 
 
homozygous for the A allele were assigned to a high phenotype group, individuals with one 
minor allele were assigned to the intermediate group and individuals with at least two 
minor alleles assigned to a low phenotype group. 
The combined haplotype built on the exonic haplotype by assigning the groups promotor 
haplotype assignations described above only to individuals who were homozygous wild type 
for all three of the exonic alleles. AO and OO individuals remained intermediate and low 
respectively, irrespective of promoter haplotype. 
 
 
Figure S2 
Blood counts in breast cancer patients during doxorubicin and cyclophosphamide 
chemotherapy according to MBL2 -221 genotype.  
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Figure S1 
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